Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win

Executive Summary

The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.

You may also be interested in...



Alkermes Ready To More Aggressively Pursue Deals After Oncology Spin-Out

After Alkermes spun out its oncology assets into a separate public entity so the company could focus exclusively on neuroscience, CEO Richard Pops said it will look externally to build its pipeline.

Takeda Stresses Orexin Commitment Despite Setback

Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback. 

Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy

The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel